Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.
about
The role of additional radiotherapy for primary central nervous system lymphomaThe role of additional radiotherapy for primary central nervous system lymphoma (PCNSL)Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphomaThe vanishing role of whole brain radiotherapy for primary central nervous system lymphomaCentral nervous system prophylaxis in diffuse large B-cell lymphoma.Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomeFirst-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.Advances in Primary Central Nervous System Lymphoma.High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.Antineoplastic agents and the associated myelosuppressive effects: a review.Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System LymphomasBiology and treatment of primary central nervous system lymphoma.Treatment options for central nervous system lymphomas in immunocompetent patients.Primary brain T-cell lymphoma of the lymphoblastic type presenting as altered mental status.High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive managementMonotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches.Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohortHigh-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphomaPharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?Adult T-cell lymphoma/leukemia presenting as isolated central nervous system T-cell lymphoma.Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoCHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphomaR-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma GroupPrimary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.Leukoencephalopathy and disseminated necrotizing leukoencephalopathy following intrathecal methotrexate chemotherapy and radiation therapy for central nerve system lymphoma or leukemia.Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.Intraocular lymphoma: update on diagnosis and management.Controversies in primary CNS lymphoma.Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader community.Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.
P2860
Q24193995-1AD15E2B-0FAF-4EA5-9E90-59C11B766BF5Q24236186-FEB61B6D-30F7-4174-98D0-4AFA07210E77Q27013785-FE62A632-BFC1-4A37-80AF-2EE60D55F7E0Q27025006-1FFA9E64-8030-4448-89BD-EAD15BE7F5C6Q30251550-28258041-7C6F-4298-AD68-15C5A76BB49BQ30411362-253C7B5B-7874-4403-8C5F-38A48B759F01Q30457046-271DA237-46FA-4E5D-8AA5-589FEE10C847Q30896676-684929D5-CDC0-458C-87FD-7FD0FBC908FFQ31007237-367B8087-C657-4D13-AD69-7FBA37246908Q33381778-5394C403-C7E6-4ADD-972B-50917AE8F6B2Q33396041-930C3F70-ED69-4E47-9393-3A409133C786Q33416656-10234C0F-A80F-459B-972B-9B0408E00866Q33417225-09AC0048-5CDC-43DC-AF29-73780684795DQ33427856-08F1FCA5-6DCC-476A-A405-5D8E5B6D3122Q33475480-BA2FCB2F-7CE0-48CA-AE56-A18F193D7998Q33510785-FAC50877-C1AB-4253-9107-0327243AE6C6Q33572213-BB76C694-FEFA-43E4-BBC9-572AF0AD2835Q33626490-689FF09D-91F7-430A-859E-140676933E79Q33774671-738ECD8B-29A6-4CB0-A164-FFF01ED0C47CQ33906988-2E5504BC-87EF-4039-840D-48FF157EEAA5Q33981252-BB7AE576-5730-41CF-A7D8-C63545579672Q34021952-CDA08078-D923-4FFE-B14B-5AC23176236CQ34132849-DA464332-B0AA-4949-AA31-11F969EACD8BQ34132988-2835E41B-32DC-490B-8EF5-9FCF2094829AQ34190457-35BAA4F6-0E7E-4837-8408-5E1C989AA834Q34837626-73B90CA0-75D5-4A34-9CCB-0C0C04B87E11Q34943963-72236766-642D-437B-9F33-D88398EC1D2DQ35105505-CFCD356C-EA4A-44C5-B201-C240CE06C68FQ35126247-F0A377D4-01D5-43C6-9E64-68AB058DD34CQ35236072-B3DCF5B4-8FBF-4ECE-B3FD-3D0B587628B1Q35599811-550C6B34-473D-471E-A7CF-385FC791EA8FQ35627088-414DB1E6-65B8-42BC-B156-FBC52CB5E3F9Q35718598-7A7DC7EB-5CBA-41C9-B35A-4560CB852BA2Q35783021-6073CF02-7680-4494-89F3-B048ED9831E4Q35892007-1AE15C0F-EF58-4BDE-AD30-175F81533C40Q36198587-70367689-045D-452A-9FBF-43024234A94FQ36261369-A79D15E3-2A10-45B2-9683-C4DFDD1BECC8Q36492327-92CE3212-579B-42D0-A40B-0C21E6670053Q36684498-43693D48-2D8D-4AED-A9E5-C2131AF64D68Q36694435-5CAA7684-0D13-4E23-B8CE-5E7F7AF5D0EF
P2860
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Treatment of primary CNS lymph ...... rapy: a report of NABTT 96-07.
@en
Treatment of primary CNS lymph ...... rapy: a report of NABTT 96-07.
@nl
type
label
Treatment of primary CNS lymph ...... rapy: a report of NABTT 96-07.
@en
Treatment of primary CNS lymph ...... rapy: a report of NABTT 96-07.
@nl
prefLabel
Treatment of primary CNS lymph ...... rapy: a report of NABTT 96-07.
@en
Treatment of primary CNS lymph ...... rapy: a report of NABTT 96-07.
@nl
P2093
P356
P1476
Treatment of primary CNS lymph ...... rapy: a report of NABTT 96-07.
@en
P2093
Alison O'Neill
Fred Hochberg
Jane Alavi
Kathryn Carson
Pamela New
Regina Priet
Stuart A Grossman
Tracy Batchelor
P304
P356
10.1200/JCO.2003.03.036
P407
P577
2003-03-01T00:00:00Z